LAUER G.M., WALKER B.D. Hepatitis C virus infection. N. Engl. J. Med., 2001, 345: 41-52.
MANNS M.P., MCHUTCHISON J.G., GORDON S.C., RUSTGI V.K., SHIFFMAN M., REINDOLLAR R., GOODMAN Z.D. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358: 958-965.
FRIED M.W., SHIFFMAN M.L., REDDY K.R., SMITH C., MARINOS G., GONCALES F.L., JR., HAUSSINGER D. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 2002, 347: 975-982.
HADZIYANNIS S.J., SETTE H., JR., MORGAN T.R., BALAN V., DIAGO M., MARCELLIN P., RAMADORI G. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 2004, 140: 346-355.
MC HUTCHISON J.G., LAWITZ E.J., SHIFFMAN M.L., MUIR A.J., GALLER G.W., MCCONE J., NYBERG L.M. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, 361: 580-593.
MICHIELSEN P., BRENARD R., BOURGEOIS N., DE GALOCSY C., DELWAIDE J., HENRION J., HORSMANS Y. et al. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-19.
ZEISEL M.B., FOFANA I., FAFI-KREMER S., BAUMERT T.F. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol., 2011, 54: 566-576.
POENISCH M., BARTENSCHLAGER R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin. Liver Dis., 2010, 30: 333-347.
ILYAS J.A., VIERLING J.M. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin. Liver Dis., 2011, 15: 515-536.
SCHUSTER C., LEFEVRE M., BAUMERT T.F. Triglyceride synthesis and hepatitis C virus production: identification of a novel host factor as antiviral target. Hepatology, 2011, 53: 1046-1048.
JONES D.M., MC LAUCHLAN J. Hepatitis C virus: assembly and release of virus particles. J. Biol. Chem., 2010, 285: 22733-22739.
MIYANARI Y., ATSUZAWA K., USUDA N., WATASHI K., HISHIKI T., ZAYAS M., BARTENSCHLAGER R. et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat. Cell. Biol., 2007, 9: 1089-1097.
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol., 2011, 55: 245-264.
GHANY M.G., NELSON D.R., STRADER D.B., THOMAS D.L., SEEFF L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011, 54: 1433-1444.
RAMACHANDRAN P., FRASER A., AGARWAL K., AUSTIN A., BROWN A., FOSTER G.R., FOX R. et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment. Pharmacol. Ther., 2012, 35: 647-662.
POORDAD F., MC CONE J., JR., BACON B.R., BRUNO S., MANNS M.P., SULKOWSKI M.S., JACOBSON I.M. et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364: 1195-1206.
JACOBSON I.M., MC HUTCHISON J.G., DUSHEIKO G., DI BISCEGLIE A.M., REDDY K.R., BZOWEJ N.H., MARCELLIN P. et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med., 2011, 364: 2405-2416.
SHERMAN K.E., FLAMM S.L., AFDHAL N.H., NELSON D.R., SULKOWSKI M.S., EVERSON G.T., FRIED M.W. et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med., 2011, 365: 1014-1024.
BACON B.R., GORDON S.C., LAWITZ E., MARCELLIN P., VIERLING J.M., ZEUZEM S., POORDAD F. et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med., 2011, 364: 1207-1217.
BRONOWICKI J.P., DAVIS M., FLAMM S., GORDON S., LAWITZ E., YOSHIDA E., GALATI J. et al. Sustained virological response (SVR) in prior Peginterferon/Ribavirin (PR) treatment failures after retreatment with Boceprevir (BOC) + PR: the Provide study interim results. J. Hepatol., 2012, S2.
ZEUZEM S., ANDREONE P., POL S., LAWITZ E., DIAGO M., ROBERTS S., FOCACCIA R. et al. Telaprevir for retreatment of HCV infection. N. Engl. J. Med., 2011, 364: 2417-2428.
HARRINGTON P.R., ZENG W., NAEGER L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology, 2012, 55: 1048-1057.
NEUMANN A.U., LAM N.P., DAHARI H., GRETCH D.R., WILEY T.E., LAYDEN T.J., PERELSON A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 1998, 282: 103-107.
BARTELS D.J., ZHOU Y., ZHANG E.Z., MARCIAL M., BYRN R.A., PFEIFFER T., TIGGES A.M. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis., 2008, 198: 800-807.
SARRAZIN C., KIEFFER T.L., BARTELS D., HANZELKA B., MUH U., WELKER M., WINCHERINGER D. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology, 2007, 132: 1767-1777.
REESINK H.W., ZEUZEM S., WEEGINK C.J., FORESTIER N., VAN VLIET A., VAN DE WETERING DE ROOIJ J., MC NAIR L. et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 2006, 131: 997-1002.
LAWITZ E., RODRIGUEZ-TORRES M., MUIR A.J., KIEFFER T.L., MC NAIR L., KHUNVICHAI A., MC HUTCHISON J.G. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J. Hepatol., 2008, 49: 163-169.
FORESTIER N., REESINK H.W., WEEGINK C.J., MC NAIR L., KIEFFER T.L., CHU H.M., PURDY S. et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology, 2007, 46: 640-648.
KIEFFER T.L., SARRAZIN C., MILLER J.S., WELKER M.W., FORESTIER N., REESINK H.W., KWONG A.D. et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology, 2007, 46: 631-639.
HEZODE C., FORESTIER N., DUSHEIKO G., FERENCI P., POL S., GOESER T., BRONOWICKI J.P. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 2009, 360: 1839-1850.
KIEFFER T.L., DE MEYER S., BARTELS D.J., SULLIVAN J.C., ZHANG E.Z., TIGGES A., DIERYNCK I. et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One, 2012, 7: e34372.
OGERT R.A., MC MONAGLE P., BLACK S. et al. Genotypic and phenotypic correlates of resistance in HCV genotype 1a and 1b infected patients treated with boceprevir plus peginterferon alpha and ribavirin. Hepatology, 2011, 54: A927.
HALFON P., LOCARNINI S. Hepatitis C virus resistance to protease inhibitors. J. Hepatol., 2011, 55: 192-206.
BARNARD R.J., ZEUZEM S., VIERLING J.M. et al. Analysis of resistanceassociated amino acid variants (RAVs) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase III clinical studies. Hepatology, 2011, 54: A164.
SHERMAN K.E., SULKOWSKI M., ZOULIM F. et al. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study. Hepatology, 2011, 54: A248.
GE D., FELLAY J., THOMPSON A.J., SIMON J.S., SHIANNA K.V., URBAN T.J., HEINZEN E.L. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009, 461: 399-401.
SUPPIAH V., MOLDOVAN M., AHLENSTIEL G., BERG T., WELTMAN M., ABATE M.L., BASSENDINE M. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet., 2009, 41: 1100-1104.
TANAKA Y., NISHIDA N., SUGIYAMA M., KUROSAKI M., MATSUURA K., SAKAMOTO N., NAKAGAWA M. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet., 2009, 41: 1105-1109.
MANGIA A., THOMPSON A.J., SANTORO R., PIAZZOLLA V., TILLMANN H.L., PATEL K., SHIANNA K.V. et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 2010, 139: 821-827, 827 e821.
STATTERMAYER A.F., STAUBER R., HOFER H., RUTTER K., BEINHARDT S., SCHERZER T.M., ZINOBER K. et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol., 2011, 9: 344-350 e342.
THOMPSON A.J., MUIR A.J., SULKOWSKI M.S., GE D., FELLAY J., SHIANNA K.V., URBAN T. et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology, 2010, 139: 120-129 e118.
POL S., AARSSENS J., ZEUZEM S., ANDREONE P., LAWITZ E.J., ROBERTS S., YOUNOSSI Z. et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial-or null-responders patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study. J. Hepatol., 2011, 54: S6.
POORDAD F., BRONOWICKI J.P., GORDON C.E., ZEUZEM S., JACOBSON I.M., SULKOWSKI M.S., POYNARD T. IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. J. Hepatol., 2011, 54: S6.
Boceprevir EU Summary of Products Characteristics. available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002332/WC500109789.pdf.
LANGE C.M., SARRAZIN C., ZEUZEM S. Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy. Aliment. Pharmacol. Ther., 2010, 32: 14-28.
Telaprevir EU Summary of Products Characteristics. available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002313/WC500115532.pdf.
GENTILE I., CARLEO M.A., BORGIA F., CASTALDO G., BORGIA G. The efficacy and safety of telaprevir-a new protease inhibitor against hepatitis C virus. Expert. Opin. Investig. Drugs, 2010, 19: 151-159.
GARG V., VAN HEESWIJK R., LEE J.E., ALVES K., NADKARNI P., LUO X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology, 2011, 54: 20-27.
ORLENT H., MATHOT R.A., VAN BOMMEL E.F., VULTO A.G., SCHALM SW., BROUWER J.T. Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1. Dig. Dis. Sci., 2005, 50: 1804-1806.
DELTENRE P., MORENO C., TRAN A., OLLIVIER I., PROVOT F., STANKE F., LAZREK M. et al. Antiviral therapy in hemodialyzed HCV patients: efficacy, tolerance and treatment strategy. Aliment. Pharmacol. Ther., 2011, 34: 454-461.
DIETERICH D.T., SORIANO V., SHERMAN K.E., GIRARD P.M., ROCKSTROH J.K., HENSHAW J., RUBIN R. et al. Telaprevir in combination with Peginterferon Alfa-2a/Ribavirin in HCV-HIV co-infected patients: SVR 12 interim analysis., 19th conference on retroviruses and opportunistic infections 2012, 2012: A46
MALLOLAS J., POL S., RIVERO A., FAINBOIM H., COOPER C., SLIM J., THOMPSON S. et al. Boceprevir plus Peginterferon/Ribavirin for the treatment of HCV/HIV co-infected patients: End of treatment (week 48) interim results. MALLOLAS J., POL S., RIVERO A., FAINBOIM H., COOPER C., SLIM J., THOMPSON S., WAHL J., GREAVES W., SULKOWSKI M. J. Hepatol., 2012, 56, S2: A50. J. Hepatol., 2012, 56: A50.
LOK A.S., GARDINER D.F., LAWITZ E., MARTORELL C., EVERSON G.T., GHALIB R., REINDOLLAR R. et al. Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1. New England Journal of Medicine, 2012, 366: 216-224.
DIENSTAG J.L., GHANY M.G., MORGAN T.R., DI BISCEGLIE A.M., BONKOVSKY H.L., KIM H.Y., SEEFF LB. et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology, 2011, 54: 396-405.
SARRAZIN C., HEZODE C., ZEUZEM S., PAWLOTSKY J.M. Antiviral strategies in hepatitis C virus infection. J. Hepatol., 2012, 56 Suppl 1: S88-100.
FOSTER G.R., HEZODE C., BRONOWICKI J.P., CAROSI G., WEILAND O., VERLINDEN L., VAN HEESWIJK R. et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology, 2011, 141: 881-889.
MORENO C., BERG T., TANWANDEE T., THONGSAWAT S., VLIERBERGHE H.V., ZEUZEM S., LENZ O. et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J. Hepatol., 2012.
SULKOWSKI M.S., SHIFFMAN M.L., AFDHAL N.H., REDDY K.R., MC CONE J., LEE W.M., HERRINE S.K. et al. Hepatitis C virus treatmentrelated anemia is associated with higher sustained virologic response rate. Gastroenterology, 2010, 139: 1602-1611, 1611 e1601.
SULKOWSKI M., REDDY R., AFDHAL N. et al. Anemia had no effect on efficacy outcomes in treatment-naïve patients who received telaprevir-based regimen in the ADVANCE and ILLUMINATE phase 3 studies. J. Hepatol., 2011, 54: S195.
SULKOWSKI M.S., POORDAD F., MANNS M.P. et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher SVR rates: analysis of previously untreated and previous-treatment-failure patients J. Hepatol., 2011, 54: S194-195.
MC HUTCHISON J.G., EVERSON G.T., GORDON S.C., JACOBSON I.M., SULKOWSKI M., KAUFFMAN R., MC NAIR L. et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med., 2009, 360: 1827-1838.
CACOUB P., BOURLIERE M., LUBBE J., DUPIN N., BUGGISCH P., DUSHEIKO G., HEZODE C. et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J. Hepatol., 2012, 56: 455-463.
REESINK H.W., FANNING G.C., FARHA K.A., WEEGINK C., VAN VLIET A., VAN 'T KLOOSTER G., LENZ O. et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology, 2010, 138: 913-921.
LAWITZ E., LALEZARI J.P., HASSANEIN T., KOWDLEY K.V., POORDAD F., SHEIKH A.M., AFDHAL N.H. et al. Once-Daily PSI-7977 Plus Peg/RBV in Treatment-naïve Patients with HCV GT1: Robust End of Treatment Response Rates are Sustained Post-treatment. Hepatology, 2011, 54: A225.
ZEUZEM S., BUGGISCH P., AGARWAL K., MARCELLIN P., SERENI D., KLINKER H., MORENO C. et al. The protease inhibitor, GS-9256, and nonnucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology, 2012, 55: 749-758.
GANE E.J., ROBERTS S.K., STEDMAN C.A., ANGUS P.W., RITCHIE B., ELSTON R., IPE D. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 2010, 376: 1467-1475.
ZEUZEM S., ASSELAH T., ANGUS P., ZARSKI J.P., LARREY D., MULLHAUPT B., GANE E. et al. Efficacy of the Protease Inhibitor BI, 201335, Polymerase Inhibitor BI, 207127, and Ribavirin in Patients with Chronic HCV infection. Gastroenterology, 2011, 141: 2047-2055.
CHAYAMA K., TAKAHASHI S., TOYOTA J., KARINO Y., IKEDA K., ISHIKAWA H., WATANABE H. et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology, 2012, 55: 742-748.
HETTIARATCHY S., PAPINI R. Initial management of a major burn: I--overview. BMJ, 2004, 328: 1555-1557.
